RLYB: Rallybio Corporation

RLYB新闻

• 21:17 Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
• 13:22 Rallybio to acquire Candid Therapeutics in $505M deal
• 10:51 Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Rallybio (NASDAQ:RLYB)
• 03:23 Rallybio首席财务官Lieber出售价值3,992美元股票
• 03:22 Lieber, Rallybio CFO, sells $3992 in shares
• 13:17 Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor
• 21:12 Rallybio announces one-for-eight reverse stock split effective Feb 6
• 15:10 Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested - TipRanks.com
• 23:15 Rallybio将于2026年2月6日实施1比8反向拆股
• 23:14 Rallybio to implement 1-for-8 reverse stock split effective February 6
• 12:05 Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study
• 17:28 Here's Why Shares in Recursion Pharmaceuticals Surged Today
• 15:15 Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio
• 13:44 Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Rallybio (NASDAQ:RLYB), Recursion Pharmaceuticals (NASDAQ:RXRX)
• 12:05 Rallybio sells HPP treatment program to Recursion for up to $25 million
• 12:13 Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116